Trinity Biotech Plc ADR (TRIB) Gains 78.95%, Causing Bears To Win

Trinity Biotech Plc ADR (NASDAQ:TRIB) has a beta value of 1.02 and has seen 116.87 million shares traded in the last trading session. The company, currently valued at $15.46M, closed the last trade at $1.36 per share which meant it gained $0.6 on the day or 78.95% during that session. The TRIB stock price is -161.03% off its 52-week high price of $3.55 and 45.59% above the 52-week low of $0.74. If we look at the company’s 10-day average daily trading volume, we find that it stood at 11.81 million shares traded. The 3-month trading volume is 172.86K shares.

Trinity Biotech Plc ADR (NASDAQ:TRIB) trade information

Sporting 78.95% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the TRIB stock price touched $1.36 or saw a rise of 6.21%. Year-to-date, Trinity Biotech Plc ADR shares have moved 54.51%, while the 5-day performance has seen it change 68.94%. Over the past 30 days, the shares of Trinity Biotech Plc ADR (NASDAQ:TRIB) have changed 64.35%. Short interest in the company has seen 94129.0 shares shorted with days to cover at 0.43.

Trinity Biotech Plc ADR (TRIB) estimates and forecasts

Figures show that Trinity Biotech Plc ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -52.45% over the past 6 months, with this year growth rate of 48.37%, compared to 11.70% for the industry. Revenue growth from the last financial year stood is estimated to be 9.44%.

1 analysts offering their estimates for the company have set an average revenue estimate of 16.5M for the current quarter. 1 have an estimated revenue figure of 16M for the next ending quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 9.90% over the past 5 years.

TRIB Dividends

Trinity Biotech Plc ADR is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.